<DOC>
	<DOCNO>NCT01697462</DOCNO>
	<brief_summary>This prospective observational study evaluate safety efficacy Xeloda ( capecitabine ) administer monotherapy patient metastatic colorectal cancer . Patients follow disease progression unacceptable toxicity occur .</brief_summary>
	<brief_title>An Observational Study Xeloda ( Capecitabine ) Patients With Metastatic Colorectal Cancer ( AXIOM )</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Metastatic colorectal cancer Receiving Xeloda accord registered indication Patients eligible Xeloda treatment accord Summary Product Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>